[(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study.
AUTHORS
McKinley
ET ,
Watchmaker
JM ,
Chakravarthy
AB ,
Meyerhardt
JA ,
Engelman
JA ,
Walker
RC ,
Washington
MK ,
Coffey
RJ ,
Manning
HC ,
. Annals of nuclear medicine. 2015 7 ; 29(6). 535-42
- PMID: 25899481 [PubMed].
- PMCID: PMC4503488.
- NIHMSID: NIHMS683548
ABSTRACT
This pilot study evaluated the utility of 3'-deoxy-3'[18F]-fluorothymidine ([(18)F]-FLT) positron emission tomography (PET) to predict response to neoadjuvant therapy that included cetuximab in patients with wild-type KRAS rectal cancers.
This pilot study evaluated the utility of 3'-deoxy-3'[18F]-fluorothymidine ([(18)F]-FLT) positron emission tomography (PET) to predict response to neoadjuvant therapy that included cetuximab in patients with wild-type KRAS rectal cancers.